Tony Shock
Director of UCB
UCB Pharma
United Kingdom
Biography
Anthony Shock received his PhD in Biochemistry from the University of London in 1987 followed by post-doctoral work at the National Heart & Lung Institute in London. He was then employed by a Biotech company called Celltech which eventually transformed into the global biopharmaceutical company, UCB. He has researched on a wide range of drug targets, both small molecule- and antibody-based therapies, including two antibody targets that have been evaluated in patients with systemic lupus erythematosus, namely epratuzumab and dapirolizumab pegol.
Research Interest
Autoimmunity; monoclonal antibodies; lupus; immunology.